SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

Human Papillomavirus Vaccination of Males: Attitudes and Perceptions of Physicians Who Vaccinate Females

By Leave a Comment

The Body

The Complete HIV/AIDS Resource
September 14, 2010

The authors assessed US physicians’ attitudes and perceptions regarding potential human papillomavirus vaccination of males in a random sample of 2,714 pediatricians and family practitioners identified in administrative claims of a US health plan as HPV vaccinators of females.

Of the 595 pediatricians and 499 family practitioners who participated, most said they would recommend HPV vaccination to males ages 11-12 (63.9 percent), 13-18 (93.4 percent), and 19-26 (92.7 percent) years. Physicians agreed that males should be vaccinated to prevent transmission of genital and anal warts (52.9 percent strongly, 36.0 percent somewhat) and to protect females from cervical cancer (75.3 percent strongly, 20.8 percent somewhat).

Countries, Mandated/Recommended Vaccines for Children Under Age 5, and Mortality Rates of Children Under Age 5

By Leave a Comment

Gaia-Health

The following pages contain three tables with the same data presented, differing only in terms of how it’s ordered.

Table 1 lists countries alphabetically.
Table 2 lists countries in order of recommended or mandated vaccinations for children under age 5.
Table 3 lists countries in order of mortality rates
of children under age 5.
_____________________
Note: All vaccine schedules are as of 2006. Some countries use combination vaccines. All schedule counts have been normalized to compare to the US schedule. For example, if a country uses an MMR-Varicella combination vaccine, it counts as 2 vaccines.

Más mercado (y víctimas) de la vacuna VPH

By Leave a Comment

Publicado por Miguel Jara el

Spain
13 de Septiembre de 2010

La campaña para expandir la polémica vacunación contra el virus del papiloma humano toma fuerza. Hasta ahora sólo se podía vacunar a las niñas pero la Comisión Europea ha extendido su administración a mujeres de hasta 45 años.

Hay algunas cosas que llaman la atención. La primera de ellas es que antes decían que esta vacuna estaba indicada para las jóvenes que no habían iniciado relaciones sexuales ya que según un estudio realizado con una de las marcas del preparado, Gardasil, del laboratorio Merck, si la joven estaba infectada había un 44,6% de posibilidades de contraer cáncer de útero. Ahora parece que obvian este estudio. Desde la Asociación de Afectadas por la Vacuna contra el Papiloma opinan:

“Creemos que este dato no se puede obviar y todas las mujeres deberían hacerse una citología o pruebas antes de recibir la vacuna para ver si están infectadas, de lo contrario en lugar de prevenir la hipotética posibilidad de contraer cáncer de útero, incrementarían esta posibilidad en un 44,6%“.

What is Wrong with the Gardasil Girls: Kahlia’s Story

By Leave a Comment

SEO Press Releases

North Hollywood, CA, September 13, 2010 — Norma Erickson, journalist for Examiner.com recently wrote an article about a 17 year-old from New Zealand adversely affected by Gardasil. Kahlia spent 2009 as a rotary exchange student in the United States as an active teen and an ambassador for her country. She had dreams and goals just like any adolescent girl her age. Those dreams came to a halt when Kahlia returned to New Zealand and had her first Gardasil injection.

A month later she was in the hospital. Just like other girls adversely affected by Gardasil, Kahlia had to withdraw from school. Her story is below:

On January 27, 2010, I had my first vaccination against cervical cancer. I started to experience headaches and nausea, which I did not relate to the vaccine at first. Over the next three weeks, I experienced uncontrollable mood swings, fatigue, insomnia, and clumsiness. I passed out a week before I was hospitalized.

On the night of February 27, I was hospitalized with tight, stabbing chest pains, shortness of breath, and headaches. My left leg had started spasming and I had a heavy feeling on my left side. After X-rays, ECG and blood tests all came back clear, I was sent home.

NCI awards $13.5 million HPV testing contract to Dutch Diagnostic Lab: What’s wrong with this picture?

By Leave a Comment

SANE Vax, Inc.

By: Norma Erickson

12 September 2010

The National Cancer Institute (NCI) announced on August 2, 2010 that it has awarded a $13.5 million contract to a Dutch diagnostic laboratory to perform reliable human papillomavirus (HPV) genotyping using a polymerase chain reaction (PCR) system with short target sequences for the cervical biopsy samples collected at the NCI.

Such reliable HPV genotyping technology was not used by the drug manufacturers in validating the efficacy of the genotype-specific HPV vaccines during the clinical trials required for Food and Drug Administration (FDA) approval, and has been rejected by the FDA for commercial distribution to clinical laboratories in the U.S. for general patient care.

This NCI contract confirms that the current FDA-approved HPV test kits for patient care in the U.S. are not reliable.

According to the pre-solicitation notice, HPV infections are very common in sexually active women and only a small subset progress to cervical cancer. When precancerous lesions appear, they may contain multiple types of HPV. It is difficult with the currently available FDA-approved HPV tests to determine whether the HPV strains present are responsible for causing the lesions, or simply there as a passenger.

News

Videos

Contact